Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person15
Evommune, Inc.
Company
Altimmune, Inc.
Company
Evolus, Inc.
Company
EVgo Inc.
Company
Inmune Bio, Inc.
Company
DUCOMMUN INC /DE/
Company
IMMUNIC, INC.
Company
Evergy, Inc.
Company
EverCommerce Inc.
Company
Immunome Inc.
Company
EVERTEC, Inc.
Company
ESG Inc.
Company
Eva Live Inc
Company
Everpure, Inc.
Company
Evercore Inc.
Company
Primary record9
Evommune, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On November 5, 2026, the Company issued a press release announcing a live webcast on EVO570. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by r
Evommune, Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. Hinova Pharmaceuticals Inc. License Transaction License Agreement On November 4, 2026, Evommune, Inc. (the “Company”) entered into an Exclusive License Agreement (the
Evommune, Inc. filed 4
SEC form 4 filed by Evommune, Inc. (CIK 2044725) on 2026-10-15.
Evommune, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On October 1, 2026, Evommune, Inc. issued a press release titled "Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Acad
Evommune, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 23, 2026, Evommune, Inc. (the Company ) issued a press release titled "Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at Eur
Evommune, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 15, 2026, Evommune, Inc. (the Company ) posted an updated corporate presentation on the Company Info page of the Company s website at https://ir.evommune.com/company-info/
Evommune, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 8, 2026, Evommune, Inc. (the Company ) issued a press release titled "Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatiti
Evommune, Inc. filed SCHEDULE 13G/A
(the "SEC") on May 7, 2026 Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person
Evommune, Inc. filed SCHEDULE 13G
0000080255-26-000581.txt : 20260814 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0000080255 XXXXXXXX LIVE COMMON STOCK 06/30/2026 0002044725 EVOMMUNE INC 30054Y107 1891 PAGE MILL RD PALO ALTO CA 94304 Rule 13d-1(b)